SynthesisWorld journal of surgical oncology2019
Is microsatellite instability-high really a favorable prognostic factor for advanced colorectal cancer? A meta-analysis.
Synthesis in World journal of surgical oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed.
- Prognostic Impact of Histologic Subtypes in Mismatch Repair-Deficient/Microsatellite Instability-High Colorectal Cancer: A Single-Center Retrospective Study of 1127 Stage 0-IV Patients.Annals of gastroenterological surgery · 2026Article
- Biomarkers in Colorectal Cancer: Actual and Future Perspectives.International journal of molecular sciences · 2024Review
- The Association of Mismatch Repair Status with Microscopically Positive (R1) Margins in Stage III Colorectal Cancer: A Retrospective Cohort Study.Annals of surgical oncology · 2024Article
- From Crypts to Cancer: A Holistic Perspective on Colorectal Carcinogenesis and Therapeutic Strategies.International journal of molecular sciences · 2024Review
- Analysis of clinical characteristics of mismatch repair status in colorectal cancer: a multicenter retrospective study.International journal of colorectal disease · 2024Article
- Minimal residual disease monitoring via ctDNA: a case report of Lynch syndrome with synchronous colorectal cancer and review of literature.Journal of gastrointestinal oncology · 2024Article
- Association between microsatellite status and characteristics and outcomes of early-onset compared to late-onset rectal cancer.International journal of colorectal disease · 2024Article
- Article
- Article
- The role of aberrant DNA methylation in cancer initiation and clinical impacts.Therapeutic advances in medical oncology · 2024Article
- PD-1 expression, among other immune checkpoints, on tumor-infiltrating NK and NKT cells is associated with longer disease-free survival in treatment-naïve CRC patients.Cancer immunology, immunotherapy : CII · 2023Article
- Review
- CD169Cancer medicine · 2023Article
- Preoperative carcinoembryonic antigen to body mass index ratio contributes to prognosis prediction in colorectal cancer.Oncology letters · 2022Article
- Article
- Impact of mismatch repair or microsatellite status on the prognosis and efficacy to chemotherapy in metastatic colorectal cancer patients: A bi-institutional, propensity score-matched study.Journal of Cancer · 2022Article
- Defects in MMR Genes as a Seminal Example of Personalized Medicine: From Diagnosis to Therapy.Journal of personalized medicine · 2021Review
- Prevalence of mismatch repair deficiency and Lynch syndrome in a cohort of unselected small bowel adenocarcinomas.Journal of clinical pathology · 2021Article
- Article
- Novel Genetic and Epigenetic Biomarkers of Prognostic and Predictive Significance in Stage II/III Colorectal Cancer.Molecular therapy : the journal of the American Society of Gene Therapy · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundStage II colorectal cancer with microsatellite instability-high (MSI-H) has been proven to have a better prognosis. However, in advanced stage, this trend remains controversial. This study aimed to explore the prognostic role of MSI-H in stage III and IV colorectal cancer (CRC) through meta-analysis.
methodsA comprehensive search was performed in PubMed, Cochrane Central Library, and Embase databases. All randomized clinical trials and non-randomized studies were included based on inclusion and exclusion criteria and on survival after a radical operation with or without chemotherapy. The adjusted log hazard ratios (HRs) were used to estimate the prognostic value between MSI-H and microsatellite-stable CRCs. The random-effects model was used to estimate the pooled effect size.
resultsThirty-six studies were included. Randomized controlled trials (RCT) and non-RCT were analyzed separately. For stage III CRCs, pooled HR for overall survival (OS) was 0.96 (95% confidence interval [CI] 0.75-.123) in the RCT subgroup and 0.89 (95% CI 0.62-1.28) in the non-RCT subgroup. For disease-free survival (DFS), the HR for the RCT group was 0.83 (95% CI 0.65-1.07), similar to the non-RCT subgroup (0.83, 95% CI 0.65-1.07). Disease-specific survival (DSS) was also calculated, which had an HR of 1.07 (95% CI 0.68-1.69) in the non-RCT subgroup. All these results showed that MSI-H has no beneficial effects in stage III CRC. For stage IV CRC, the HR for OS in the RCT subgroup was 1.23 (95% CI 0.92-1.64) but only two RCTs were included. For non-RCT study, the combined HR for OS and DFS was 1.10 (95% CI 0.77-1.51) and 0.72 (95% CI 0.53-0.98), respectively, suggesting the beneficial effect for DFS and non-beneficial effect for OS.
conclusionFor stage III CRC, MSI-H had no prognostic effect for OS, DFS, and DSS. For stage IV CRC, DFS showed a beneficial result, whereas OS did not; however, the included studies were limited and needed further exploration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.